Cambridge Investment Research Advisors’s T. Rowe Price US Equity Research ETF TSPA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.4M Buy
429,904
+76,928
+22% +$3.53M 0.05% 410
2026
Q1
$14.4M Buy
352,976
+145,294
+70% +$6.21M 0.04% 476
2025
Q4
$8.88M Buy
207,682
+8,687
+4% +$369K 0.02% 630
2025
Q3
$8.34M Buy
198,995
+65,833
+49% +$2.65M 0.02% 646
2025
Q2
$5.18M Buy
133,162
+98,328
+282% +$3.54M 0.02% 832
2025
Q1
$1.23M Sell
34,834
-1,590
-4% -$58.9K ﹤0.01% 1695
2024
Q4
$1.35M Buy
36,424
+21,731
+148% +$807K ﹤0.01% 1641
2024
Q3
$531K Sell
14,693
-3,117
-18% -$108K ﹤0.01% 2362
2024
Q2
$613K Sell
17,810
-10,737
-38% -$353K ﹤0.01% 2128
2024
Q1
$937K Buy
28,547
+2,460
+9% +$76.3K ﹤0.01% 1778
2023
Q4
$767K Buy
+26,087
New +$718K ﹤0.01% 1831

Other funds holding TSPA

Cambridge Investment Research Advisors's TSPA Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its T. Rowe Price US Equity Research ETF (TSPA) stake by 22% in Q2 2026, buying an estimated $3.53M and bringing the position to 429,904 shares worth $20.4M. The position accounts for 0.05% of the portfolio, ranked #410.

Cambridge Investment Research Advisors first reported a position in TSPA in Q4 2023 and has held it in 11 quarters since. 69 funds tracked by Wall St. Rank hold TSPA as of Q2 2026.

  • Cambridge Investment Research Advisors held 429,904 shares of T. Rowe Price US Equity Research ETF worth $20.4M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 76,928 T. Rowe Price US Equity Research ETF shares in Q2 2026, an estimated $3.53M.
  • T. Rowe Price US Equity Research ETF made up 0.05% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #410 holding.
  • Cambridge Investment Research Advisors first reported a position in T. Rowe Price US Equity Research ETF in Q4 2023 and has held it in 11 quarters since.
  • 69 funds tracked by Wall St. Rank held T. Rowe Price US Equity Research ETF as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.